UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 329, 2010

Trubion Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware (State or Other Jurisdiction of Incorporation)		001-33054 (Commission File No.)		52-2385898 (IRS Employer Identification No.)

2401 Fourth Avenue, Suite 1050, Seattle, WA 98121
(Address of Principal Executive Offices, including Zip Code)

(206) 838-0500
(Registrant’s Telephone Number, Including Area Code)

None
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


þ		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01.		Other Events.

On September 829, 2010, Trubion Pharmaceuticals, Inc. (“Trubion”), ~~announced~~Emergent ~~that~~BioSolutions ~~the~~Inc. (“Emergent”), Uand 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc.S., ~~Department~~an indirect wholly-owned subsidiary of ~~Justice~~Emergent ~~and~~entered ~~Federal~~into ~~Trade~~an ~~Commission~~Amendment ~~granted~~No. 1 ~~early~~(the ~~termination~~“Amendment”) ofto the Agreement ~~waiting~~and ~~period~~Plan ~~under~~of Merger entered into by the ~~Hart-Scott-Rodino~~ ~~Antitrust~~parties ~~Improvements~~on ~~Act~~August 12, of2010, ~~1976~~pursuant to which Emergent will acquire Trubion (~~“HSR~~the ~~Act~~“Merger”),. asPursuant ~~amended~~to the Amendment, ~~with~~Trubion ~~respect~~agreed to terminate, effective no later than the ~~planned~~ ~~acquisition~~effective date of ~~Trubion~~the Merger, its 401(k) plan, as well as any other defined contribution qualified retirement plan maintained by ~~Emergent~~it ~~BioSolutions~~or ~~Inc~~an affiliate. AExcept as ~~copy~~so amended, the Merger Agreement remains in full force and effect. This summary is qualified by the full text of the ~~press~~Amendment, ~~release~~which is filed ~~herewith~~ as Exhibit 99.1 hereto and is hereby incorporated by reference.

Additional Information ~~about the Transaction~~ and Where to Find It

InThis communication is being made in connection with the ~~transaction~~Merger among Emergent, Trubion and certain of Emergent’s ~~intends~~direct toand ~~file~~indirect ~~with~~wholly-owned ~~the~~subsidiaries. ~~Securities~~Emergent ~~and~~has ~~Exchange Commission~~filed (with the SEC~~) a~~ a registration statement on Form S-4, ~~and~~which ~~Trubion~~contains a prospectus relating to the securities Emergent intends to ~~file~~issue in the proposed Merger. Trubion has filed a definitive proxy statement in connection with the ~~SEC~~proposed Merger and mailed the definitive proxy statement and other relevant ~~mail~~documents to ~~its~~Trubion’s stockholders. aStockholders ~~proxy~~of ~~statement/prospectus.~~Emergent ~~Investors~~and Trubion and ~~stockholders~~other interested persons are ~~urged~~advised to read the registration statement and definitive proxy statement, and amendments thereto because these documents contain important information about Trubion, Emergent and the proposed Merger. The definitive proxy statement~~/prospectus~~ ~~and~~was ~~other~~mailed ~~relevant~~on or about September 27, 2010 to Trubion stockholders of record on September 21, 2010. Stockholders may obtain a copy of the documents filed with the SEC, ~~when~~without ~~they become available~~charge, asat ~~well~~the asSEC’s ~~any~~website ~~amendments~~at http://www.sec.gov or ~~supplements~~by directing a request to: ~~the~~Emergent ~~documents because~~BioSolutions ~~they~~Inc., ~~will~~Attn: ~~contain~~Investor ~~important~~Relations, ~~information~~2273 ~~about~~Research Boulevard, ~~Emergent~~Suite 400, ~~Trubion~~Rockville, ~~and~~Maryland ~~the~~20850, ~~merger~~or Trubion Pharmaceuticals, Inc., Attention: Investor Relations, 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.

~~The~~Participants ~~registration~~in statement, the proxy statement/prospectus and any other relevant materials (when they become available), and any other documents filed by Emergent and/or Trubion with the SEC, may be obtained free of charge at the SEC’s web site at www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by directing a written request to: Emergent BioSolutions Inc., Attn: Investor Relations, 2273 Research Boulevard, Suite 400, Rockville, Maryland 20850, or Trubion Pharmaceuticals, Inc., Attn: Investor Relations, 2401 4th Avenue, Suite 1050, Seattle, Washington 98121. Investors and stockholders are urged to read the registration statement, the proxy statement/prospectus and the other relevant materials when they become available. Solicitation

~~Participants~~Emergent, Trubion and their respective directors and officers may be deemed participants in ~~Solicitations~~the solicitation of proxies from Trubion’s stockholders. Information regarding Emergent’s directors and officers is available in Emergent’s proxy statement for its 2010 annual meeting of stockholders and its 2009 annual report on Form 10-K, which were filed with the SEC and are available at the SEC’s website at http://www.sec.gov. Information regarding Trubion’s directors and officers is available in Trubion’s proxy statement for its 2010 annual meeting of stockholders and its 2009 annual report on Form 10-K, which were filed with the SEC and are available at the SEC’s website at http://www.sec.gov. Information regarding Trubion’s directors and officers is also contained in Trubion’s definitive proxy statement in connection with the Merger which is available at the SEC’s website. Emergent’s and Trubion’s stockholders may obtain additional information about the interests of Trubion’s directors and officers in the Merger by reading Trubion’s definitive proxy statement.

Emergent, Trubion and their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies in connection with the merger. Information regarding Emergent’s directors and officers is available in Emergent’s proxy statement on Schedule 14A for its 2010 annual meeting of stockholders, which was filed with the SEC on April 9, 2010. Information regarding Trubion’s directors and executive officers is available in Trubion’s proxy statement on Schedule 14A for its 2010 annual meeting of stockholders, which was filed with the SEC on April 21, 2010. Additional information regarding the interests of such potential participants will be included in the proxy statement and the other relevant documents filed with the SEC when they become available.


Item 9.01.		Financial Statements and Exhibits.

(d) Exhibits.

99.1 ~~Press~~Amendment ~~Release~~No. ~~issued~~1 byto ~~Trubion~~Agreement ~~Pharmaceuticals,~~and ~~Inc.~~Plan of Merger dated September 829, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TRUBION PHARMACEUTICALS, INC.
Date: September 8, 2010	By:	/s/ John A. Bencich
Date: September 30, 2010	By:	/s/ John A. Bencich
		Name:	John A. Bencich
		Title:	Vice President and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.		~~Description~~		Description
~~99.1~~	99.1	~~Press Release issued by Trubion Pharmaceuticals, Inc dated September 8, 2010~~		Amendment No. 1 to Agreement and Plan of Merger dated September 29, 2010

Filing Compare · Trubion Pharmaceuticals, Inc